Objective: To investigate retrospectively the efficacy of steroids in patients with acute-onchronic liver failure (ACLF) precipitated by hepatitis B.
| INTRODUCTION
Acute-on-chronic liver failure (ACLF) is characterized by acute deterioration of liver function in patients with underlying chronic liver diseases, which results in a high mortality despite the improvements in medical therapies over the years. 1 Although liver transplantation is the definitive treatment strategy for end-stage liver diseases, it is often not available in areas with limited resources. Researchers have investigated the efficacies of various medications for ACLF, including granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and β-blockers. [2] [3] [4] However, prospective studies including large sample sizes are required to confirm their effects further.
The hallmark of ACLF is intensive systemic inflammation like sepsis. 5 Corticosteroids are known to suppress the inflammatory process and have been demonstrated to reduce mortality in patients with acute liver failure (ALF) 6, 7 but not in others. 8 The variation might be attributed to the differences in inclusion criteria, precipitating events, ethnic background and life-supporting strategies among different studies. However, the efficacy of steroids in patients with ACLF remains unknown.
One of the major obstacles of clinical studies on ACLF lies in the heterogeneity of patients with the condition. From 2013 to 2014 a new classification and scoring system, the Chronic Liver Failure (CLIF)
Sequential Organ Failure Assessment (CLIF-SOFA) score 1 and its simplified version, the CLIF-Consortium (CLIF-C) ACLF score 9 have been established for ACLF in the Western population, with emphasizing extrahepatic organ failure. The new classification system was also validated in the Eastern population in whom the leading cause of ACLF is the spontaneous activation of hepatitis B. 10 However, the CLIF-C criteria did not solve all the problems of patient heterogeneity, as recent studies have revealed that patients having ACLF induced by intrahepatic and extrahepatic insults differ in their prognoses. 11 Regrouping patients with ACLF based on different etiologies, precipitating events and different scoring systems can help identify those who will benefit from steroid therapy. We thus performed this retrospective cohort study to validate the effectiveness of corticosteroids in treating Chinese patients with ACLF that was precipitated by the activation of hepatitis B.
| PATIENTS AND METHODS

| Patients
Medical records of the patients with ACLF who were admitted to the Shandong Province, China]) were used, the dose of each type of corticosteroid was converted to an equivalent dose of prednisone (based on its anti-inflammatory potency) in order to render the data comparable. The dose, duration, and type of corticosteroid were up to the discretion of each doctor, but their general approach was to administer the equivalent of 1 mg prednisone/kg weight for 5-7 days and the dose was gradually tapered off by 0.5 mg/kg for 2 days, then at a total dose of 10-15 mg for 2-3 days, 5 mg for 2-3 days until the corticosteroids are ceased.
| Follow-up and data collection
The patients were followed up for one year, their survival data and rate of liver transplantation were recorded. Their vital signs and laboratory test results were recorded. CLIF-C ACLF scores, and the model for end-stage liver disease (MELD) score were then calculated based on all these available parameters obtained. Complications due to liver decompensation such as ascites, hepatic encephalopathy, renal dysfunction, respiratory and circulatory dysfunction were documented.
The occurrence of infection was recorded in accordance with the criteria proposed in a previous study. 11 In clinical practice we documented the frequent elevation of body temperature (>38 C) in patients with ACLF. Sometimes the source of infection could not be identified precisely despite a thorough diagnostic workup, and multiple bacterial cultures yielded negative results. We defined such cases as unidentified infection.
| End-points
The primary end-point was non-transplant survival at day 60, the secondary end-points included non-transplant survival at 12 months, biochemical tests, and the changes in CLIF-C OF/CLIF-C ACLF and MELD scores.
| Statistical analysis
Statistical analyses were performed by using the SPSS 22.0 (IBM, Armonk, NY, USA) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). Continuous variables were presented as mean ± standard deviation, whereas categorical variables were expressed as numbers and percentages. Differences in the parameters between patients in the control and steroid groups were compared using the unpaired parametric t-test for continuous variables and Fischer's exact test for categorical variables when appropriate. Univariate and multivariate regression analyses were performed by using the proportional hazards model. A two-sided P value of less than 0.05 was considered statistically significant.
3 | RESULTS
| Patients' characteristics
In total, 431 patients were identified and included in the initial analysis, among them 37 were excluded due to insufficient data or perished within one week, 49 were excluded due to infection prior to the onset of liver injury, and another 52 patients were excluded due to being compounded by other causes of liver injury. Therefore, 293 patients were recruited in the final analysis. Among them, 162 received at least five consecutive doses of corticosteroids and were included in the steroid group, and the remainders were assigned to the control group (n = 131). The flowchart of patient enrollment is shown in Figure 1 .
Their basic characteristics and laboratory test results (except platelet count), organ failure, as defined by the CLIF criteria, and severity of their liver diseases (graded based on the CLIF-C ACLF grade, CLIF-C score, and MELD score) were comparable between the steroid and control groups ( Figure 2A , with a log-rank test revealing that the cumulative 60-day survival rate did not differ between the two groups (P = 0.181). Moreover, we found that the difference in cumulative survival by the last follow up visit was not statistically significant as well (log-rank test, P = 0.098; Figure 2B Previous studies have suggested that steroids may be more effective in patients with acute liver failure that was not thought to be too late to be conservatively treated. 13, 14 We then tested this possibility in patients with ACLF. The patients were regrouped based on their ACLF grade or MELD score. In patients with ACLF 0-1, the 60-day survival of the control group was 70.8% (63/89), which was not Figure 2C ). Subsequently, patients were assigned to their MELD quartiles. None of the MELD groups receiving steroid showed a survival benefit ( Figure 2D , Table S1 ). Age was a significant predictor of survival across the studies, as younger patients were more likely to survive. 1, 9, 11 To examine the confounding effect of age, we analyzed survival within subgroups that were divided upon age and identified a non-significant difference between the control and steroid groups ( Figure 2E ).
| Infection was observed more frequently in the steroid group compared with the control group
Infection was more frequently detected in the steroid group than in the control group. The 60-day cumulative incidence of infections was also significantly higher in the steroid group (P < 0.001; Figure 3 , Table 2 ). Nearly all kinds of infections occurred with a higher frequency in the steroid group, especially pulmonary infection (18.5% vs.
6.9%, P = 0.003) and invasive fungal or other opportunistic infections (7.4% vs. 0%, P = 0.001). Bacteremia and spontaneous bacterial peritonitis were exceptions (Table 2) . Unidentified infection (when the body temperature >38 C but the exact site of infection could not be identified), was more common in the steroid group as well, although the difference was not statistically significant (P = 0.055). Table S2 shows the patients with invasive fungal and other opportunistic infections.
All such cases received steroid treatment and only two patients among them survived.
| Factors associated with 60-day mortality or transplantation
We performed univariate and multivariate analysis to identify the factors associated with 60-day mortality and liver transplantation. In univariate analysis, patients' age, baseline CLIF-C ACLF grade, baseline MELD score >20, pulmonary infection and overall infections were significantly associated with 60-day mortality or transplantation. However, in multivariate analysis, only older age (hazard ratio [HR] 1.035, P < 0.001), baseline MELD score >20 (HR 1.811, P = 0.010) and baseline CLIF-C ACLF grade (grade 2-3 vs. grade 0-1, HR 2.117, P = 0.001) were independent risk factors for mortality and liver transplantation.
Steroid treatment was not correlated with mortality or iver transplantation (Table 3) .
| DISCUSSION
In this retrospective cohort study we demonstrated that steroid treatment did not improve the overall 60-day and 1-year transplant-free survival of patients with ACLF, even in the subgroups divided by their ACLF grade, MELD score and age. Overall, infections within 60 days after the initiation of the treatment, especially pulmonary infection and invasive fungal or other opportunistic infection, were significantly more prevalent in the steroid group than in the control group. A Intensive systemic and liver inflammation is the hallmark feature of both ACLF 5 and ALF. 15 As a potent anti-inflammatory agent, glucocorticosteroids used for the treatment of ALF have been investigated with various outcomes. Studies in Asian populations commonly reported a more favorable outcome than those conducted in Western populations, [6] [7] [8] possibly due to the differences in ethnicity, background liver disease and precipitating events. Nevertheless, the inclusion criteria and treatment strategies also varied widely. Steroid pulse treatment in the first 2 to 3 days was more common in the Asian studies. Few studies have reported the efficacy of steroid treatment in patients with ACLF. 16 The heterogeneity of these patients is part of the difficulty that underlies such studies. Furthermore, current definitions (including CLIF-C criteria) are still suboptimal for Asian patients with ACLF who are frequently precipitated by hepatitis B. 17 For example, various studies reported that the 90-day mortality in patients with ACLF grade 0 was less than 10%. 4, 18 Nonetheless, the 60-day mortality in patients with ACLF 0 in our cohort was over 20%, FIGURE 3 Cumulative 60-day incidence of (A) all infections in the control vs. steroid group (log-rank test, P < 0.001), (B) spontaneous bacterial peritonitis (SBP) (P = 0.309), and (C) pulmonary infection (PI) (P = 0.006). ( ) control group; ( ) steroid group; ( ) control group censored; ( ) steroid group censored which is much higher. In another study, the 28-day mortality in ACLF 0 patients of similar characteristics was also reported to be over 10%. 17 The latest research has indicated that the CLIF-C criteria have failed to identify the patients with ACLF precipitated by hepatitis B at a risk of death in an early stage. 17 Unlike previous studies, overt decompensation events were not documented in any patients, and minor decompensation events were probably neglected. Recently, it has been suggested that conservative treatment for patients with ACLF 2-3 is futile. However, fewer than one-third of our patients were classified into the CLIF-C ACLF 2-3 group at baseline. In short, the patients included in our study were generally homogeneous and it was not too late to treat them conservatively.
In this study treatment with steroids led to suboptimal outcomes compared with standard life-supporting treatment. The cumulative 60-day and 1-year survival rates were not significantly different between the steroid and control groups. We speculated that steroids might be beneficial for the patients with a less severe form of the disease. 13, 14 To test this hypothesis, patients were assigned to subgroups based on their ACLF grade and MELD score. A stratified analysis failed to prove that steroid treatment is beneficial for survival.
Although age was a significant predictor of survival or mortality across the studies, the beneficial roles of steroid treatment in their individual age groups were not identified. The use of steroids and immunosuppressive agents in patients infected with HBV has been linked to the reactivation of hepatitis B, which occasionally leads to fatal outcomes. 18, 19 Therefore, we used low doses of steroids in this study. In addition to steroids, all patients with HBV-associated-ACLF in our cohort received nucleotide analogues as well. Since there was no statistically significant difference in the HBV DNA levels between the steroid-treated and control groups at both entry point and day 28 ± 7. It was unlikely that steroids led to a detectable activation of HBV replication in this study.
Infection is well-known as a major driving force of liver and kidney deterioration, and this has been indicated as a predictor of mortality in patients with liver failure. [20] [21] [22] Since steroid use is usually contraindicated during infection, patients with infection were excluded from the study upon their admission to hospital. In this study, the overall infection rate was significantly higher in the patients treated with steroids than in the control group, and all cases of invasive fungal infection were correlated with steroid use. A univariate analysis revealed that overall infection and pulmonary infection were risk factors for 60-day mortality. Thus, any benefit of steroid treat- In conclusion, steroid treatment fails to show a survival benefit for patients with ACLF who commonly suffered from hepatitis B flare-ups and from existing compensated liver diseases. Before further studies address the efficacy of steroids in certain subgroups (eg, younger patients with specific background liver disease and precipitating events) and prophylactics against steroids-induced infection, we cannot recommend routine steroid use in patients with ACLF.
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